Xu Gao

Xu Gao


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2020 in Nature
Verified
Journal Article
Closed access
PDF file
JLJing Li
Jing Li
CXChuanliang Xu
Chuanliang Xu
HLHyung Joo Lee
Hyung Joo Lee
SRShancheng Ren
Shancheng Ren
XZXiaoyuan Zi
Xiaoyuan Zi
YSYinghao Sun
Yinghao Sun

1 February 2019 in Developmental Cell
Verified
Journal Article
Closed access
JZJinfang Zhang
Jinfang Zhang
MCMing Chen
Ming Chen
YZYasheng Zhu
Yasheng Zhu
XDXiangpeng Dai
Xiangpeng Dai
FDFabin Dang
Fabin Dang
WWWenyi Wei
Wenyi Wei

1 October 2022 in Cancer Science
Verified
Journal Article
Open access
MWMENG WANG
MENG WANG
SLShijia Luan
Shijia Luan
XFXiang Fan
Xiang Fan
Jie WangJie Wang
Jie Wang
JHJu Huang
Ju Huang
DHdong han
dong han
For its various important functions in cells, phosphatase and tensin homolog‐induced kinase 1 (PINK1) has drawn considerable attention for the role it plays in early‐onset Parkinson's disease. In recent years, emerging evidence has supported the hypothesis that PINK1 plays a part in regulating many physiological and pathophysiological processes in cancer cells, including cytoplasmic homeostasis, cell survival, and cell death. According to the findings of these studies, PINK1 can function as a tumor promoter or suppressor, showing a duality that is dependent on the context. In this study we review the mechanistic characters relating to PINK1 based on available published data from peer‐reviewed articles, The Cancer Genome Atlas data mining, and cell‐based assays. This mini review focuses on some of the interplays between PINK1 and the context and recent developments in the field, including its growing involvement in mitophagy and its nonmitophagy organelles‐related function. This review aims to help readers better grasp how PINK1 is functioning in cell physiological and pathophysiological processes, especially in cancer biology.

1 July 2016 in Urology
Verified
Journal Article
Closed access
YCYifan Chang
Yifan Chang
MQMin Qu
Min Qu
LWLinhui Wang
Linhui Wang
BYBo Yang
Bo Yang
RCRui Chen
Rui Chen
XGXu Gao
Xu Gao

1 January 2020 in Asian Journal of Andrology
Verified
Journal Article
Open access
XGXu Gao
Xu Gao
YSYinghao Sun
Yinghao Sun
DKDe-Pei Kong
De-Pei Kong
RCRui Chen
Rui Chen
CZChun-Lei Zhang
Chun-Lei Zhang
NTNa Ta
Na Ta
J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society

20 August 2024 in Cell Reports Medicine
Verified
Journal Article
Open access
RSRui Sun
Rui Sun
JAJun A
Jun A
HYHaolan Yu
Haolan Yu
YWYan Wang
Yan Wang
MHMiaoxia He
Miaoxia He
CYChenghua Yang
Chenghua Yang
Prostate cancer (PCa) is the most common malignant tumor in men. Currently, there are few prognosis indicators for predicting PCa outcomes and guiding treatments. Here, we perform comprehensive proteomic profiling of 918 tissue specimens from 306 Chinese patients with PCa using data-independent acquisition mass spectrometry (DIA-MS). We identify over 10,000 proteins and define three molecular subtypes of PCa with significant clinical and proteomic differences. We develop a 16-protein panel that effectively predicts biochemical recurrence (BCR) for patients with PCa, which is validated in six published datasets and one additional 99-biopsy-sample cohort by targeted proteomics. Interestingly, this 16-protein panel effectively predicts BCR across different International Society of Urological Pathology (ISUP) grades and pathological stages and outperforms the D'Amico risk classification system in BCR prediction. Furthermore, double knockout of NUDT5 and SEPTIN8, two components from the 16-protein panel, significantly suppresses the PCa cells to proliferate, invade, and migrate, suggesting the combination of NUDT5 and SEPTIN8 may provide new approaches for PCa treatment.